Healthcare provider profile · identity verified

Lavern E Orlang, MD

Family Practice · EAST LIVERPOOL, OH · NPI 1134120132

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	214	54
Amlodipine Besylate	Amlodipine Besylate	192	44
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	190	34
Lisinopril	Lisinopril	154	41
Metformin Hcl	Metformin Hcl	147	45
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	119	27
Albuterol Sulfate Hfa	Albuterol Sulfate	114	21
Levothyroxine Sodium	Levothyroxine Sodium	113	31
Omeprazole	Omeprazole	111	22
Tamsulosin Hcl	Tamsulosin Hcl	103	18
Gabapentin	Gabapentin	96	15
Alprazolam	Alprazolam	91	16
Rosuvastatin Calcium	Rosuvastatin Calcium	88	26
Potassium Chloride	Potassium Chloride	87	18
Pantoprazole Sodium	Pantoprazole Sodium	86	19
Lorazepam	Lorazepam	85	18
Meloxicam	Meloxicam	83	17
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	78	19
Eliquis	Apixaban	72	suppressed
Doxepin Hcl	Doxepin Hcl	57	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	57	suppressed
Furosemide	Furosemide	52	suppressed
Pravastatin Sodium	Pravastatin Sodium	49	12
Pioglitazone Hcl	Pioglitazone Hcl	48	11
Metoprolol Succinate	Metoprolol Succinate	47	15
Temazepam	Temazepam	44	suppressed
Trulicity	Dulaglutide	42	suppressed
Carvedilol	Carvedilol	40	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	40	suppressed
Sertraline Hcl	Sertraline Hcl	40	11
Ropinirole Hcl	Ropinirole Hcl	38	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	38	suppressed
Metoprolol Tartrate	Metoprolol Tartrate	37	suppressed
Oxycodone Hcl	Oxycodone Hcl	36	suppressed
Simvastatin	Simvastatin	36	suppressed
Tramadol Hcl	Tramadol Hcl	36	suppressed
Pregabalin	Pregabalin	35	suppressed
Clonazepam	Clonazepam	33	suppressed
Losartan Potassium	Losartan Potassium	33	suppressed
Mirtazapine	Mirtazapine	33	suppressed
Tizanidine Hcl	Tizanidine Hcl	33	suppressed
Diazepam	Diazepam	32	suppressed
Allopurinol	Allopurinol	31	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	31	suppressed
Trazodone Hcl	Trazodone Hcl	31	suppressed
Famotidine	Famotidine	30	suppressed
Clopidogrel	Clopidogrel Bisulfate	29	suppressed
Glimepiride	Glimepiride	29	suppressed
Hydrochlorothiazide	Hydrochlorothiazide	29	suppressed
Metformin Hcl Er	Metformin Hcl	29	suppressed
Budesonide-Formoterol Fumarate	Budesonide/Formoterol Fumarate	28	suppressed
Ibuprofen	Ibuprofen	27	suppressed
Atenolol	Atenolol	26	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	26	suppressed
Prednisone	Prednisone	26	suppressed
Buspirone Hcl	Buspirone Hcl	25	suppressed
Dextroamphetamine-Amphetamine	Dextroamphetamine/Amphetamine	25	suppressed
Ondansetron Hcl	Ondansetron Hcl	25	suppressed
Digoxin	Digoxin	23	suppressed
Montelukast Sodium	Montelukast Sodium	23	suppressed
Ibu	Ibuprofen	21	suppressed
Spironolactone	Spironolactone	20	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	19	suppressed
Ondansetron Odt	Ondansetron	19	suppressed
Spiriva Respimat	Tiotropium Bromide	18	suppressed
Duloxetine Hcl	Duloxetine Hcl	16	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	15	suppressed
Fluticasone Propionate	Fluticasone Propionate	15	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	14	suppressed
Warfarin Sodium	Warfarin Sodium	14	suppressed
Bupropion Hcl Sr	Bupropion Hcl	13	suppressed
Celecoxib	Celecoxib	13	suppressed
Finasteride	Finasteride	13	suppressed
Zaleplon	Zaleplon	13	suppressed
Irbesartan	Irbesartan	12	suppressed
Methylprednisolone	Methylprednisolone	12	suppressed
Paroxetine Hcl	Paroxetine Hcl	12	suppressed
Symbicort	Budesonide/Formoterol Fumarate	12	suppressed
Donepezil Hcl	Donepezil Hcl	11	suppressed
Eszopiclone	Eszopiclone	11	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error